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Abstract
Background: New chemotherapy regimens for patients with colorectal cancer have improved
survival, but at the cost of clinical toxicity. Oxaliplatin, an agent used in first-line therapy for
metastatic colorectal cancer, causes acute and chronic neurotoxicity. This study was performed to
carefully assess the incidence, type and duration of oxaliplatin neurotoxicity.
Methods: A detailed questionnaire was completed after each chemotherapy cycle for patients
with metastatic colorectal cancer enrolled in a phase I trial of oxaliplatin and capecitabine. An
oxaliplatin specific neurotoxicity scale was used to grade toxicity.
Results:  Eighty-six adult patients with colorectal cancer were evaluated. Acute neuropathy
symptoms included voice changes, visual alterations, pharyngo-laryngeal dysesthesia (lack of
awareness of breathing); peri-oral or oral numbness, pain and symptoms due to muscle contraction
(spasm, cramps, tremors). When the worst neurotoxicity per patient was considered, grade 1/2/3/
4 dysesthesias and paresthesias were seen in 71/12/5/0 and 66/20/7/1 percent of patients. By cycles
3, 6, 9, and 12, oxaliplatin dose reduction or discontinuation was needed in 2.7%, 20%, 37.5% and
62.5% of patients.
Conclusion: Oxaliplatin-associated acute neuropathy causes a variety of distressing, but transient,
symptoms due to peripheral sensory and motor nerve hyperexcitability. Chronic neuropathy may
be debilitating and often necessitates dose reductions or discontinuation of oxaliplatin. Patients
should be warned of the possible spectrum of symptoms and re-assured about the transient nature
of acute neurotoxicity. Ongoing studies are addressing the treatment and prophylaxis of oxaliplatin
neurotoxicity.
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Background
Colorectal cancer is the third commonest cause of non-
skin cancers in men and in women with a total of 146,940
new cases and 56,730 deaths estimated in the United
States in 2004 [1]. Approximately 25% of patients present
with metastatic disease. Despite improvements in adju-
vant therapy, a substantial number of patients with local-
ized disease will ultimately develop metastatic disease.
The 5-year survival for patients with metastatic colorectal
cancer is less than 10%. The role of chemotherapy in
patients with unresectable disease as a neoadjuvant
approach to make resection possible is currently being
explored in clinical trials; retrospective analyses suggest
that patients who can undergo complete surgical resection
of hepatic metastases after neoadjuvant chemotherapy
may have a survival approaching 50% [2].
The standard chemotherapy regimen used as first-line
treatment of colorectal cancer for many years was bolus 5-
FU modulated by (LV), but this has recently been super-
seded by newer combination regimens involving LV-mod-
ulated 5-FU given as a mixed bolus and continuous
infusion with the addition of either oxaliplatin or irinote-
can. Oxaliplatin, an organoplatinum complex, produces
cytotoxicity via the formation of DNA adducts which
interfere with DNA replication and transcription and lead
to induction of apoptosis. The different spectrum of clini-
cal activity and toxicity of oxaliplatin compared to cispla-
tin and carboplatin is believed to be due to its 1,2-
diaminocyclohexane structure, which forms bulkier DNA
adducts. A Phase III trial in patients with metastatic color-
ectal cancer comparing oxaliplatin and biweekly LV-mod-
ulated mixed bolus and infusional 5-FU (FOLFOX 4) to
bolus 5-FU/LV given daily for five days every month dem-
onstrated superiority in both response rate and progres-
sion-free survival [3]. Another Phase III trial demonstrated
a significant survival advantage with FOLFOX-4 compared
to irinotecan and bolus 5-FU/LV (median survival 19.5 vs
15 months, p = 0.0001) [4]. A randomized trial compar-
ing sequential administration of biweekly LV-modulated
mixed bolus and infusional 5-FU combined with either
oxaliplatin (FOLFOX 4) or irinotecan (FOLFIRI) followed
by the other regimen at the time of disease progression
showed equivalent survival of about 21 months for both
sequences [5]. The Food and Drug Administration
approved FOLFOX-4 as salvage therapy of metastatic
colorectal cancer in August, 2002, and as first-line therapy
in January, 2004. Oxaliplatin has also shown activity in
other platinum-sensitive tumors, including in some can-
cer patients with documented cisplatin-refractory disease
[6-8].
The dose-limiting toxicity of oxaliplatin is neurotoxicity
[9,10]. The neurotoxicity has two distinct manifestations:
acute, transient symptoms are due to peripheral sensory
and motor neuron hypersensitivity; cumulative, persistent
symptoms are due to chronic peripheral sensory neuropa-
thy [9-12]. The pathogenesis of the acute neuropathy is
believed to be due to a channelopathy (a temporary dys-
function of an ion channel in the nerve membrane), while
chronic sensory neuropathy may be a result of direct,
cumulative neurotoxic effects resulting from platinum
accumulation in the dorsal root ganglion [11-15]. A
number of grading systems have been used to report oxali-
platin-associated neurotoxicity. Clinical studies involving
oxaliplatin appear to have largely described the chronic
sensory neuropathy, whereas information on the acute
peripheral motor and sensory neuropathy is more limited.
In order to obtain information on the incidence and type
of oxaliplatin-associated acute and chronic neurotoxicity,
we devised a questionnaire to be used in a phase I study
of oxaliplatin and capecitabine
Methods
Voluntary subjects
Patients were enrolled in a Phase I study examining the
safety and feasibility of administering a fixed dose of
oxaliplatin with escalating doses of capecitabine to
patients with advanced colorectal or small bowel adeno-
carcinoma. The protocol was approved by the Cancer
Therapy Evaluation Program, NCI, and Institutional
Review Boards of the NCI and the National Naval Medical
Center. All patients gave written informed consent. As part
of the trial, we collected information on neurotoxicity
experienced by the patients during therapy. We previously
reported information obtained using EMG and NCS as an
objective assessment of the neurotoxicity [11,12]. The
objective of the present analysis was to determine the inci-
dence, type and duration of neurotoxicity using a ques-
tionnaire that was filled in by a research nurse during an
interview with the subject.
Chemotherapy and dose modifications
Oxaliplatin 130 mg/m2 was infused by vein over 2-hours
on day one, while a total daily dose of capecitabine rang-
ing from 1,200 to 3,000 mg/m2 was given in two divided
doses on days 1–5 and 8–12 of a planned 21-day cycle. As
part of this intramural NCI research study, patients were
hospitalized overnight at no charge following the first
infusion of oxaliplatin to allow monitoring for acute neu-
rotoxicity, and patients were interviewed the next morn-
ing to record any acute symptoms. Protocol therapy was
continued until evidence of disease progression occurred,
unacceptable toxicity developed, or the patient elected to
withdraw. A neurotoxicity grading system developed by
the pharmaceutical sponsor was used to describe the par-
esthesias/dysesthesias, which could be cold-induced or
not: grade 1, symptoms of short duration that resolve and
do not interfere with function; grade 2, interfering with
some functions, but not with the basic activities of dailyBMC Cancer 2005, 5:116 http://www.biomedcentral.com/1471-2407/5/116
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living; grade 3, pain or functional impairment that inter-
fere with activities of daily living; grade 4, persistent symp-
toms that are disabling or life-threatening.
If subjects experienced acute, transient neurotoxicity that
was particularly bothersome, the duration of infusion was
increased to six hours in subsequent cycles. The dose of
oxaliplatin was decreased by 25% if grade 2 neurotoxicity
persisted between cycles. The dose of oxaliplatin was
decreased by 25% for grade 3 neurotoxicity that resolved
before the next cycle of therapy, while the drug was dis-
continued for either grade 3 neurotoxicity that persisted
between cycles, or for grade 4 neurotoxicity, regardless of
duration. In a subset of twelve patients, an empiric trial of
carbamazepine was begun five days prior to the second
dose of oxaliplatin and continuing for a total of seven
days as previously reported to assess any possible impact
on acute neurotoxicity symptoms and neurophysiologic
studies [11].
Neurologic assessment
Subjects were asked to keep a daily diary of side-effects. A
research nurse interviewed the subjects and filled out a
questionnaire that characterized the incidence and type of
neurotoxicity symptoms and how long they lasted. The
questionnaire was divided into 3 parts addressing the
upper extremity, the lower extremity and orofacial area
(Tables 1, 2, 3), and was completed after each 3-week
cycle of chemotherapy. Objective neurological assessment
was also obtained by physical exam in all patients at the
start of each cycle. The results of serial EMG and NCS tests
in a subset of patients have been reported previously [12].
Results
Demographics
Eighty-six patients (56 males/30 females) were included
in this assessment; 69 were Caucasian, 14 were African-
American, and three were Hispanic. The median age was
56 years (range 26–74). The location of the primary
tumor was colon (76 patients), rectum (8) or appendix
(2). The median ECOG performance status was 1 (range
0–2). The majority of the patients had undergone prior
surgical resection of their primary tumor; 90% had
received prior 5-FU, and two-thirds had received prior iri-
notecan-based therapy.
Use and analysis of the questionnaire
The questionnaire was a tool that was designed to help
capture the variety and location of potential neurotoxic
side effects that the patients might experience. Patients
were specifically queried about symptoms occurring the
upper extremities, lower extremities, and face/mouth.
Patients were asked if they had each of the specific symp-
toms, yes or no. If yes, then there were two parts to the
assessment: first, whether the patient felt the symptoms
were minimal to very prominent; second, whether the
symptoms affected the daily activities hardly at all
through a range that the subject was extremely bothered
by the symptoms in a functional sense. The following
scores on the questionnaire corresponded to the follow-
ing neurotoxicity grades: 1,2 = grade 1; 3 = grade 2; 4 =
grade 3; 5 = grade 4.
Neuropathy
Dysesthesia, herein defined as painful or distressing sen-
sations experienced in the absence of stimulation, was
experienced by 87.2% of patients. Paresthesia, herein
defined as non-painful but abnormal sensations such as
numbness or tingling, was experienced by 94.3% of
patients at some point during oxaliplatin-based chemo-
therapy (Table 4). For most patients, the worst grade of
dysesthesia and paresthesia was grade 1 (70.9% and
66.3% respectively). However, some patients experienced
functional impairment affecting activities of daily living.
One patient developed an ascending sensorimotor syn-
drome after the fourth dose of oxaliplatin that led to pro-
found weakness in the upper and lower extremities
without respiratory impairment, although it was uncer-
tain whether this was due to oxaliplatin or due to the
development of an unrelated neurological condition [16].
Dysesthesias occurred more often in the face than in the
extremities, perhaps due to acute, painful cold sensitivity
experienced while eating, drinking or handling a cold
object (Figure 1). Paresthesias occurred more often in the
hands and feet, which may be consistent with the glove
and stocking distribution associated with chronic periph-
eral neuropathies.
The duration of the neuropathy increased as the cumula-
tive exposure to oxaliplatin increased (Table 5). After the
first cycle of chemotherapy, the median duration of
dysesthesia was only 5 days, whereas it was 21 days in
patients who received 12 cycles of chemotherapy. The
median duration of paresthesia after cycle one was 7 days,
but after cycle 12 was 21 days or longer. The proportion of
patients who complained of dysesthesia of any grade after
one cycle of chemotherapy (73%) was similar to the pro-
portion of patients who complained of paresthesia (77%)
(Figure 2). After six cycles of chemotherapy, 68% of
patients complained of dysesthesia, whereas 92% of
patients complained of paresthesia. The increased inci-
dence of paresthesia is consistent with the development of
a cumulative sensory neuropathy in most patients. The
relatively stable incidence of dysesthesia may reflect that
such symptoms are more commonly associated with the
transient hyperexcitability phenomenon. The acute symp-
toms do not appear to be cumulative phenomenon. By
cycles 9 and 12, the incidence of grade 3 dysesthesia and
paresthesia became noticeable. Remarkably, someBMC Cancer 2005, 5:116 http://www.biomedcentral.com/1471-2407/5/116
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Table 1: Questionnaire documenting upper extremity symptoms of acute and chronic neuropathy experienced during or after 
oxaliplatin-based chemotherapy.
Upper Extremity Symptoms If you had symptoms during the last cycle....
How much of the symptoms did you have? Did the symptoms affect your daily activities?
Do you have.... Hardly any → Very much Hardly at all bothered →  Extremely bothered
Tingling (pins and needles) Yes No 1 2 3 4 5 1 2 3 4 5
N u m b n e s s Y e s N o 123451 2 3 4 5
Difficulty telling the difference 
between rough and smooth surfaces
Y e s N o 123451 2 3 4 5
Difficulty feeling hot things Yes No 1 2 3 4 5 1 2 3 4 5
Difficulty feeling cold things Yes No 1 2 3 4 5 1 2 3 4 5
A greater than normal sense of 
touch (i.e. putting on gloves)
Y e s N o 123451 2 3 4 5
Burning pain or discomfort without 
cold
Y e s N o 123451 2 3 4 5
Burning pain or discomfort with 
cold
Y e s N o 123451 2 3 4 5
Difficulty identifying objects in your 
hand (i.e. coin)
Y e s N o 123451 2 3 4 5
Do you have involuntary hand 
movements
Y e s N o 123451 2 3 4 5




If you had symptoms during the last cycle....
How much of the symptoms did you have? Did the symptoms affect your daily activities?
Do you have.... Hardly any → Very much Hardly at all bothered → Extremely bothered
T i n g l i n g  ( p i n s  a n d  n e e d l e s ) Y e s N o 1 2 3 4 5 12345
N u m b n e s s Y e s N o 1 2 3 4 5 12345
Difficulty telling the difference 
between rough and smooth 
surfaces
Y e s N o 1 2 3 4 5 12345
D i f f i c u l t y  f e e l i n g  h o t  t h i n g s Y e s N o 1 2 3 4 5 12345
D i f f i c u l t y  f e e l i n g  c o l d  t h i n g s Y e s N o 1 2 3 4 5 12345
A greater than normal sense of 
touch (i.e. discomfort with 
socks)
Y e s N o 1 2 3 4 5 12345
Burning pain or discomfort 
without cold
Y e s N o 1 2 3 4 5 12345
Burning pain or discomfort with 
cold
Y e s N o 1 2 3 4 5 12345
L e g s  f e e l  h e a v y Y e s N o 1 2 3 4 5 12345BMC Cancer 2005, 5:116 http://www.biomedcentral.com/1471-2407/5/116
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patients did not complain of any paresthesia or dysesthe-
sia even after 12 cycles of therapy. By cycles three and six,
oxaliplatin dose reductions for neurotoxicity were needed
in 2.7% and 20% of patients. By cycle 9, 37.5% of patients
required a dose reduction (4% of these had discontinued
oxaliplatin); by cycle 12, 62.5% of remaining patients had
discontinued oxaliplatin.
Acute neurotoxicity symptoms were recorded with partic-
ular focus on the nature of the symptoms. The common-
est symptom experienced was cold sensitivity (>80%),
which was often reported to be painful by patients (Figure
3). Pain with the initial bite of food was noted by about
60% of the patients, most likely attributed to masticatory
spasm. Some symptoms were of very short duration (last-
ing only seconds or at most a few minutes), while other
lasted for several hours (ptosis, sensation of leg heavi-
ness); both short- and longer-lived symptoms could be of
major concern to both patient and physician. The most
distressing symptom was pharyngolaryngeal dysesthesia,
which patients often described as a poor awareness that
they were breathing. Other patients noted transient
hoarseness or change in their voice, and some com-
mented on visual field deficits or ocular pain. Despite the
fact that symptoms resolved spontaneously over a short
period of time, many patients required anxiolytics to
reduce their level of distress. A subset of patients who
received carbamazepine as a prophylactic measure to
reduce the symptoms of acute neuropathy did not appear
to derive any benefit from this approach [12].
Discussion
Oxaliplatin is an integral component of the various FOL-
FOX regimens, which have become a standard treatment
for metastatic and node-positive colorectal cancer
[3,4,17]. Encouraging results have been reported from
phase II trials using oxaliplatin in combination with
pemetrexed, raltitrexed or capecitabine in patients with
metastatic colorectal cancer [18-24]. Enthusiasm
regarding the efficacy of oxaliplatin/5-FU/LV regimens
has been tempered by the associated neurotoxicity which
can significantly impair the quality of life of patients and
limits the optimal use of oxaliplatin. Many published tri-
als provide limited details concerning the precise type and
location of neurotoxicities experienced, and most appear
to have focused on the cumulative sensory neuropathy.
Table 3: Questionnaire documenting oral or facial symptoms of acute and chronic neuropathy experienced during or after oxaliplatin-
based chemotherapy.
Oral/Facial Symptoms If you had symptoms during the last cycle....
How much of the symptoms did you have? Did the symptoms affect your daily activities?
Do you have.... Hardly any → Very much Hardly at all bothered → Extremely bothered
J a w  p a i n Y e s N o 1 2 3 4 5 12345
E y e l i d s  d r o o p i n g Y e s N o 1 2 3 4 5 12345
T h r o a t  d i s c o m f o r t Y e s N o 1 2 3 4 5 12345
E a r  p a i n Y e s N o 1 2 3 4 5 12345
T i n g l i n g  i n  m o u t h Y e s N o 1 2 3 4 5 12345
D i f f i c u l t y  w i t h  s p e e c h Y e s N o 1 2 3 4 5 12345
B u r n i n g  o r  d i s c o m f o r t  o f  y o u r  e y e s Y e s N o 1 2 3 4 5 12345
L o s s  o f  a n y  v i s i o n Y e s N o 1 2 3 4 5 12345
F e e l i n g  s h o c k / p a i n  d o w n  b a c k Y e s N o 1 2 3 4 5 12345
P r o b l e m s  w i t h  b r e a t h i n g Y e s N o 1 2 3 4 5 12345
Table 4: Worst grade of toxicity across all cycles of therapy
No toxicity Grade 1 Grade 2 Grade 3 Grade 4
Dyesthesia 12.8% 70.9% 11.6% 4.7% 0%
Paresthesia 5.7% 66.3% 19.8% 7% 1.2%BMC Cancer 2005, 5:116 http://www.biomedcentral.com/1471-2407/5/116
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Data on the reported incidence of neuropathy from rand-
omized trials, presented in Table 6, may be influenced by
the toxicity scale employed, the cumulative oxaliplatin
dose, and schedule of administration (3–5,1 7, 25–29).
For three trials that employed 85 mg/m2 oxaliplatin given
over 2 hours as first-line therapy for metastatic colorectal
cancer, the incidence of grade 3 or worse neuropathy was
reported to be a mean of 15.4%. A higher incidence of
grade 3 neuropathy (31–34%) was reported when
oxaliplatin was given at 20 mg/m2 as a 24-hour infusion
daily for 5 days every 3 weeks or as 100 mg/m2 over 2
hours every 2 weeks. The incidence of grade 3 neuropathy
was lower with IROX, in which 85 mg/m2 is given over 2
hours every 3 weeks. The lowest incidence of serious neu-
rotoxicity has been reported in trials in which FOLFOX is
used as second- or third-line salvage therapy, presumably
because the cumulative dose of oxaliplatin is less than
when employed as first-line therapy.
Although the symptoms associated with acute peripheral
sensory and motor nerve hyperexcitability seem to be
transient in nature, they can cause distressing symptoms
in patients. We used a questionnaire that was filled out by
the research nurse during a face- to face interview with the
patient. All patients kept a daily calendar diary of side
effects, and were interviewed the morning after the initial
dose of oxaliplatin. This approach provided detailed
information on the incidence, type, location and duration
Location of dysesthesias/paresthesias during therapy with  oxaliplatin and capecitabine (n = 86 subjects) Figure 1
Location of dysesthesias/paresthesias during therapy with 













































Percentage of subjects with dysesthesias/paresthesias as a  function of number of cycles Figure 2
Percentage of subjects with dysesthesias/paresthesias as a 
function of number of cycles. The number of subjects at each 
cycle is shown in parentheses.
Percentage of subjects experiencing specific types of symp- toms due to acute peripheral sensory and motor nerve  hyperexcitability (n = 86 subjects) Figure 3
Percentage of subjects experiencing specific types of symp-
toms due to acute peripheral sensory and motor nerve 
hyperexcitability (n = 86 subjects).
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Cramps in hands or legs
Heavy sensation in legs
Throat symptoms: cold-induced
Throat Pain: Any
Jaw pain with first bite
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of neuropathy experienced by patients. Since all research
subjects were admitted for their first cycle of chemother-
apy, close observation for acute neurological symptoms
and next-day interviews with patients was possible. These
measures may have facilitated identification of symptoms
or signs that perhaps would otherwise have gone
unreported.
Our study demonstrated that most patients experience
either dysesthesia or paresthesia at some point during
their treatment, although the worst toxicity grade was
Table 5: Duration of dysesthesia and paresthesias (21 day cycles)
Dysesthesias
Cycle number Median duration (days) Percent persisting ≥ 14 days Percent persisting ≥ 21 days
1 5 9.5% 3.2%
3 7 14.3% 6.1%
6 10.5 38.2% 17.6%
9 13.5 50% 37.5%
12 21 60% 60%
Paresthesias
Cycle number Median duration (days) Percent persisting ≥ 14 days Percent persisting ≥ 21 days
1 7 19.7% 6.1%
3 12.5 35.6% 18.6%
6 14 54.3% 37%
9 = 21 86.4% 77.3%
12 = 21 83.3% 83.3%
Table 6: Cumulative chronic sensory neuropathy rates in selected phase III trials involving oxaliplatin and 5-FU based combination 
chemotherapy
Ref. Regimen Oxaliplatin Dose: mg/m2 Planned Oxaliplatin Dose 
intensity: mg/m2/wk
Treatment ≥ grade 3
25 OX + FU/LVa chronotherapy Both arms: 20 days 1–5 q 3 wk 20/10.5 hr CI; 
peak at 4:00 pm
33.3 First line 16%
Constant rate 20/24 hr CI 31%
26 OX + FU/LVb 125/6 hr day 1 q 3 wk 10:00 am to 4:00 pm 41.7 First line 10%
3 FOLFOX 4 85/2 hr day 1 q 2 wk 42.5 First line 18.2%
4 FOLFOX 4 85/2 hr day 1 q 2 wk 42.5 First line 18%
IROX 85/1.5 hr day 1 q 3 wk 28.3 7%
5 FOLFOX 6 100/2 hr day 1 q 2 wk 50 First line 34%
27 FUFOX 50/2 hr days 1, 8, 15, 22 q 5 wkc 40 First line 17%
28 FUFOX 50/x hr days 1, 8, 15, 22 q 5 wkc 40 First line 25%
CAPOX 70/x hr d 1, 8 q 3 wk 46.7 16%
17 FOLFOX 4 85/2 hr day 1 q 2 wk 42.5 Adjuvant 12%
5 FOLFOX 6 100/2 hr day 1 q 2 wk 50 Second lined 20%
29 FOLFOX 4 85/2 hr day 1 q 2 wk 42.5 Second or third linee 3%f
FOLFOX: oxaliplatin and biweekly FULV2; IROX: oxaliplatin and irinotecan;
FUFOX: oxaliplatin and weekly 24 hour infusional 5-FU/LV; CAPOX: capecitabine and oxaliplatin
a 5-FU 600 mg/m2 and LV 300 mg/m2 daily for 5 days over 12 hr with peak at either 04:00 am or over 24 hr by constant rate infusion; b 5-FU 700 mg/
m2 and LV 300 mg/m2 daily for 5 days over 12 hr with peak at 04:00 am; c after the first four cycles, oxaliplatin given every 2 weeks; d patients had 
previously progressed on FOLFIRI; e Grade 3–4 acute, cold-sensitive paresthesia also occurred in 3% of patients.BMC Cancer 2005, 5:116 http://www.biomedcentral.com/1471-2407/5/116
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grade 1 in most patients. Due to stringent dose modifica-
tion guidelines, only a small proportion of patients expe-
rience serious functional impairment. However, as the
cumulative dose of oxaliplatin increases, patients are
more likely to experience paresthesia due to a cumulative
sensory neuropathy. In patients who receive more than 6
cycles of chemotherapy (projected maximum cumulative
dose on this every 3-week schedule of 780 mg/m2), the
neuropathy can become persistent and affect the subject's
ability to perform routine activities of daily living. Oxali-
platin-associated cumulative sensory neuropathy is slowly
reversible in most patients [9,10,17].
Among the various acute, transient neuropathic symp-
toms experienced by patients, cold sensitivity is the most
common form, but it is rarely debilitating since patients
can adapt to avoid cold stimuli. The temporary loss of
awareness of breathing is relatively uncommon, but is
probably the most alarming symptom. It is imperative
that patients are warned about these symptoms and their
transient nature prior to chemotherapy administration.
Such patients can talk, and their breath exhalation is audi-
ble. Acute oxaliplatin-associated neurotoxicity can result
in other disturbing symptoms such as visual field cuts,
blurred vision and ptosis. Administration of FOLFOX
regimens require a centrally implanted venous catheter to
deliver outpatient infusional 5-FU. Since our study
involved oral capecitabine, patients were not required to
have central venous access. However, due to the occur-
rence of whole arm pain in the extremity used to infuse
oxaliplatin, and due to extravasation injuries, we
amended our protocol to recommend placement of cen-
tral venous access devices.
There is no standard treatment for oxaliplatin-related neu-
rotoxicity. A variety of strategies have been employed to
prevent or treat oxaliplatin neurotoxicity [10,30-39],
including carbamazepine, gabapentin, alpha lipoic acid,
amifostine, glutathione, and celecoxib. The largest experi-
ence is the retrospective analysis of the benefit of infusing
magnesium and calcium prior to oxaliplatin administra-
tion in 96 patients compared to 65 patients who did not
receive magnesium/calcium. The percentage of patients
with grade 3 distal paresthesia was lower in Ca/Mg group
(7% vs 26%, p = 0.001), and acute symptoms such as dis-
tal and lingual paresthesia were much less frequent and
severe in the Ca/Mg group. The authors concluded that
Ca/Mg infusions seemed to reduce the incidence and
intensity of acute oxaliplatin-induced symptoms and
might delay cumulative neuropathy [32]. A large, rand-
omized trial will be required to clarify the link between
acute, transient symptoms and the likelihood of
development of chronic sensory neuropathy, and confirm
whether strategies such as Ca/Mg infusions reduce the
neurotoxicity without impacting on the anti-tumor
efficacy.
Another approach involves the administration of six
cycles of FOLFOX-7, followed by the use of biweekly
FULV2 for 12 cycles; oxaliplatin was then re-introduced
for six cycles, or earlier if disease progression occurred on
FULV2 [40]. The intention is to allow recovery from neu-
rotoxicity during the oxaliplatin-free period which may
allow the re-introduction of oxaliplatin. Preliminary
results demonstrate that this is a convenient regimen with
no detrimental effects on efficacy.
Several cases have been reported in the literature concern-
ing peripheral neuropathy in association with 5-FU and
capecitabine therapy. Stein reported two subjects who
developed symptoms of pain and weakness in the lower
extremities while receiving fluorouracil and levamisole
[41]. EMG revealed axonal and demyelinting polyneurop-
athy involving small and large fibers. Two patients treated
in a phase I trial of oral 5-FU, leucovorin and eniluracil,
an inhibitor of dihydropyrimidine dehydrogenase, devel-
oped delayed onset symptoms of unsteady gait and
reduced sensation in the legs [42]. EMG and NCS revealed
sensorimotor polyneuropathy. Saif reported two patients
who experienced either right leg weakness with foot drop
or perioral and upper extremity paresthesias with
capecitabine [43]. EMG and NCS showed sensorimotor
peripheral neuropathy in both patients. In each of these
three reports, other common etiologies of peripheral neu-
ropathy were excluded. Couch et al reported a patient
given capecitabine who experience acute onset of neu-
romuscular symptoms, the most prominent of which was
trismus, [44]. Peripheral neuropathy may thus represent
an extremely rare complication of fluorouracil or capecit-
abine therapy. The possible contribution of capecitabine
to the neurologic symptoms in the patients in the current
trial is unclear. However, the neurophysiologic studies
obtained shortly after administration of oxaliplatin are
unique and are reminiscent of neuromyotonia.
Conclusion
The use of oxaliplatin chemotherapy is increasing and has
resulted in significant improvements in outcomes in
colorectal cancer. However, oxaliplatin-associated neuro-
toxicity can cause detrimental effects to the patient's qual-
ity of life and may require dose reduction or
discontinuation. Our study provides detailed information
on the incidence, type and duration of oxaliplatin neuro-
toxicity. Further understanding of oxaliplatin-associated
neurotoxicity is necessary to warn patients of potential
side effects and to facilitate strategies to prevent or treat
this neurotoxicity. Optimizing the quality of life of cancer
is of paramount importance. Continued research on
oxaliplatin will help achieve this goal while alsoBMC Cancer 2005, 5:116 http://www.biomedcentral.com/1471-2407/5/116
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providing further progress with respect to clinical benefit
outcomes.
Abbreviations
5-FU, 5-fluorouracil; LV, leucovorin; FOLFOX, a combina-
tion of folinic acid (leucovorin), 5-FU and oxaliplatin
given on a fortnightly schedule; FOLFIRI, a combination
of folinic acid (leucovorin) given with 5-FU and
irinotecan on a fortnightly schedule; NCI, National Can-
cer Institute; EMG, electromyogram; NCS, nerve conduc-
tion study
Competing interests
The author(s) declare that they have no competing
interests.
Authors' contributions
GDL participated in the conduct of this trial and drafted
the manuscript. MW participated in the conduct of this
trial. MGQ participated in the conduct of this trial. SF par-
ticipated in the conduct of this trial. NH participated in
the conduct of this trial. BS participated in the conduct of
this trial. RT participated in the conduct of this trial. JLG
conceived of the study, coordinated its design and imple-
mentation, and wrote the final version. All authors read
and approved the final manuscript.
References
1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer
EJ, Thun MJ, American Cancer Society: Cancer Statistics, 2004.  CA
Cancer J Clin 2004, 54:8-29.
2. Giacchetti S, Itzhaki M, Gruia G, Adam R, Zidani R, Kunstlinger F,
Brienza S, Alafaci E, Bertheault-Cvitkovic F, Jasmin C, Reynes M, Bis-
muth H, Misset JL, Levi F: Long-term survival of patients with
unresectable colorectal cancer liver metastases following
infusional chemotherapy with 5-fluorouracil, leucovorin,
oxaliplatin and surgery.  Ann Oncol 1999, 10:663-669.
3. De Gramont A, Figer M, Seymour M, Homerin M, Hmissi A, Cassidy
J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, Le
Bail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti
A: Leucovorin and fluorouracil with or without oxaliplatin as
first-line treatment in advanced colorectal cancer.  J Clin Oncol
2000, 18:2938-2947.
4. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK,
Williamson SK, Findlay BP, Pitot HC, Alberts S: A randomized con-
trolled trial of fluorouracil plus leucovorin, irinotecan, and
oxaliplatin combinations in patients with previously
untreated metastatic colorectal cancer.  J Clin Oncol 2004,
22:23-30.
5. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D,
Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet
C, de Gramont A: OLFIRI followed by FOLFOX6 or the
reverse sequence in advanced colorectal cancer: a rand-
omized GERCOR study.  J Clin Oncol 2004, 22:229-237.
6. Faivre S, Kalla S, Cvitkovic E, Bourdon O, Hauteville D, Dourte LM,
Bensmaine MA, Itzhaki M, Marty M, Extra JM: Oxaliplatin and pacl-
itaxel combination in patients with platinum- pretreated
ovarian carcinoma: an investigator-originated compassion-
ate- use experience.  Ann Oncol 1999, 10:1125-1128.
7. Kollmannsberger C, Rick O, Derigs HG, Schoeffski P, Metzner B,
Hartmann JT, Rick O, Stengele K, Hohloch K, Spott C, Kanz L, Boke-
meyer C: Activity of oxaliplatin in patients with relapsed or
cisplatin-refractory germ cell cancer: a study of the German
Testicular Cancer Study Group.  J Clin Oncol 2002, 20:2031-2037.
8. Lorusso PM: Oxaliplatin in tumors other than colorectal
cancer.  Oncology (Huntingt) 2000, 14(Suppl 11):33-37.
9. Gamelin E, Gamelin L, Bossi L, Quasthoff S: Clinical aspects and
molecular basis of oxaliplatin neurotoxicity: current man-
agement and development of preventive measures.  Semin
Oncol 2002, 29(Supp 15):21-33.
10. Grothey A: Oxaliplatin-safety profile: neurotoxicity.  Semin
Oncol 2003, 30(Suppl 15):5-13.
11. Wilson RH, Lehky T, Thomas RR, Quinn MG, Floeter MK, Grem JL:
Acute oxaliplatin-induced peripheral nerve
hyperexcitability.  J Clin Oncol 2002, 20:1767-1774.
12. Lehky TJ, Leonard GD, Wilson RH, Grem JL Floeter MK: Oxalipla-
tin-induced neurotoxicity: acute hyperexcitability and
chronic neuropathy.  Muscle and Nerve 2004, 29:387-392.
13. Grolleau F, Gamelin L, Boisdron-Celle M, Lapied B, Pelhate M, Game-
lin E: A possible explanation for a neurotoxic effect of the
anticancer agent oxaliplatin on neuronal voltage-gated
sodium channels.  J Neurophysiol 2001, 85:2293-2297.
14. Holmes J, Stanko J, Varchenko , Ding H, Madden VJ, Bagnell CR,
Wyrick SD, Chaney SG: Comparative neurotoxicity of oxalipla-
tin, cisplatin, and ormaplatin in a Wistar rat model.  Toxicol Sci
1998, 46:342-351.
15. Cavaletti G, Tredici G, Petruccioli MG, Donde E, Tredici P, Marmiroli
P, Minoia C, Ronchi A, Bayssas M, Etienne GG: Effects of different
schedules of oxaliplatin treatment on the peripheral nervous
system of the rat.  Eur J Cancer 2001, 37:2457-2463.
16. Leonard GD, Wagner MR, Quinn MG, Grem JL: Severe disabling
sensory-motor polyneuropathy during oxaliplatin-based
chemotherapy.  Anticancer Drugs 2004, 15:733-735.
17. Andre T, Boni C, Mounedji-Boudiaf L, Tabernero J, Hickish T,
Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de
Gramont A, Multicenter International Study of Oxaliplatin/5-Fluorou-
racil/Leucovorin in the Adjuvant Treatment of Colon Can-
cer(MOSAIC) Investigators: Oxaliplatin, fluorouracil, and
leucovorin as adjuvant treatment for colon cancer.  New Eng J
Med 2004, 350:2343-2451.
18. Atkins JN, Jacobs S, Wieand S, Smith R, John W, Renshaw G, Col-
angelo L, Geyer C Jr, Wolmark N: Pemetrexed and oxaliplatin
for first-line treatment of patients with advanced colorectal
cancer: A phase II trial of the NSABP foundation research
program.  Proc Am Soc Clin Oncol 2003, 22:276. abstr 1108
19. Cascinu S, Graziano F, Ferrau F, Catalano V, Massacesi C, Santini D,
Silva RR, Barni S, Zaniboni A, Battelli N, Siena S, Giordani P, Mari D,
Baldelli AM, Antognoli S, Maisano R, Priolo D, Pessi MA, Tonini G,
Rota S, Labianca R: alitrexed plus oxaliplatin (TOMOX) as first-
line chemotherapy for metastatic colorectal cancer. A phase
II study of the Italian Group for the study of gastrointestinal
tract carcinomas (GISCAD).  Ann Oncol 2002, 13:716-720.
20. Borner MM, Dietrich D, Stupp R, Morant R, Honegger H, Wernli M,
H e r r m a n n  R ,  P e s t a l o z z i  B C ,  S a letti P, Hanselmann S, Muller S,
Brauchli P, Castiglione-Gertsch M, Goldhirsch A, Roth AD: Phase II
study of capecitabine and oxaliplatin in first- and second-line
treatment of advanced or metastatic colorectal cancer.  J Clin
Oncol 2002, 20:1759-1766.
21. Cassidy J, Tabernero J, Twelves C, Brunet R, Butts C, Conroy T,
Debraud F, Figer A, Grossmann J, Sawada N, Schoffski P, Sobrero A,
Van Cutsem E, Diaz-Rubio E: XELOX (capecitabine plus oxalipl-
atin): active first-line therapy for patients with metastatic
colorectal cancer.  J Clin Oncol 2004, 22:2084-2091.
22. Shields AF, Zalupski MM, Marshall JL, Meropol NJ: Treatment of
advanced colorectal carcinoma with oxaliplatin and capecit-
abine: a phase II trial.  Cancer 2004, 100:531-537.
23. Zeuli M, Nardoni C, Pino MS, Gamucci T, Gabriele A, Ferraresi V,
Giannarelli D, Cognetti F: Phase II study of capecitabine and
oxaliplatin as first-line treatment in advanced colorectal
cancer.  Ann Oncol 2003, 14:1378-1382.
24. Scheithauer W, Kornek GV, Raderer M, Schull B, Schmid K, Kovats E,
Schneeweiss B, Lang F, Lenauer A, Depisch D: Randomized multi-
center phase II trial of two different schedules of capecitab-
ine plus oxaliplatin as first-line treatment in advanced
colorectal cancer.  J Clin Oncol 2003, 21:1307-1312.
25. Levi FA, Zidani R, Vannetzel JM, Perpoint B, Focan C, Faggiuolo R,
Chollet P, Garufi C, Itzhaki M, Dogliotti L: Chronomodulated ver-
sus fixed-infusion-rate delivery of ambulatory chemotherapy
with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in
patients with colorectal cancer metastases: a randomized
multi-institutional trial.  J Natl Cancer Inst 1994, 86:1608-1617.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2005, 5:116 http://www.biomedcentral.com/1471-2407/5/116
Page 10 of 10
(page number not for citation purposes)
26. Giacchetti S, Perpoint B, Zidani R, Le Bail N, Faggiuolo R, Focan C,
Chollet P, Llory JF, Letourneau Y, Coudert B, Bertheaut-Cvitkovic F,
Larregain-Fournier D, Le Rol A, Walter S, Adam R, Misset JL, Levi F:
Phase III multicenter randomized trail of oxaliplatin added
to chronomodulated fluorouracil-leucovorin as first-line
treatment of metastatic colorectal cancer.  J Clin Oncol 2000,
18:136-147.
27. Grothey A, Deschler B, Kroenig H, Ridwelski K, Reichardt P,
Kretzschmar A, Clemens M, Hirschmann W, Lorenz M, Asperger W,
Buechele T, Schmoll H-J: Phase III study of bolus 5-fluorouracil
(5-FU)/folinic acid (FA) (Mayo) vs weekly high-dose 24 h 5-
FU infusion/FA+oxaliplatin (OXA) (FUFOX) in advanced
colorectal cancer (ACRC).  Proc Am Soc Clin Oncol 2002, 21:129a.
abstr 512
28. Arkenau HT, Schmoll H, Kubicka S, Seufferlein T, Reichardt P, Freier
W, Graeven U, Grothey A: Phase III trial of infusional 5-fluorou-
racil/folinic acid plus oxaliplatin versus capecitabine plus
oxaliplatin as first line treatment in advanced colorectal car-
cinoma: Results of an interim safety analysis.  Proc Am Soc Clin
Oncol 2004, 22(14S):256s. abstract 3546
29. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ram-
anathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller
DG:  Superiority of oxaliplatin and fluorouracil-leucovorin
compared with either therapy alone in patients with pro-
gressive colorectal cancer after irinotecan and fluorouracil-
leucovorin: interim results of a Phase III trial.  J Clin Oncol 2003,
21:2059-2069.
30. Lersch C, Schmelz R, Eckel F, Erdmann J, Mayr M, Schulte-Frohlinde
E, Quasthoff S, Grosskreutz J, Adelsberger H: Prevention of oxali-
platin-induced peripheral sensory neuropathy by car-
bamazepine in patients with advanced colorectal cancer.  Clin
Colorectal Cancer 2002, 2:54-58.
31. Mariani G, Garrone O, Granetto C, Numico G, LaCiura P, Grecchi G,
DiCostanzo G, Merlano M: Oxaliplatin induced neuropathy:
could gabapentin be the answer?  Proc Am Soc Clin Oncol 2000,
19:609a. abstr 2397
32. Gamelin L, Boisdron-Celle M, Delva R, Guerin-Meyer V, Ifrah N,
Morel A, Gamelin E: Prevention of oxaliplatin-related
neurotoxicity by calcium and magnesium infusions: a retro-
spective study of 161 patients receiving oxaliplatin combined
with 5-fluorouracil and leucovorin for advanced colorectal
cancer.  Clin Cancer Res 2004, 10:4055-4061.
33. Pederiva S, Caspar CB: Management of acute oxaliplatin-
related peripheral sensory neuropathy with magnesium and
calcium.  Proc Am Soc Clin Oncol 2004, 22:297s. abstr 3715
34. Cascinu S, Catalano V, Cordella L, Labianca R, Giordani P, Baldelli AM,
Beretta GD, Ubiali E, Catalano G: Neuroprotective effect of
reduced glutathione on oxaliplatin-based chemotherapy in
advanced colorectal cancer: A randomized, double-blind,
placebo-controlled trial.  J Clin Oncol 2002, 20:3478-3483.
35. Gedlicka C, Scheithauer W, Schull B, Kornek GV: Effective treat-
ment of oxaliplatin-induced cumulative polyneuropathy with
alpha-lipoic acid.  J Clin Oncol 2002, 20:3359-3360. (letter)
36. Penz M, Kornek GV, Raderer H, Ulrich-Pur H, Fiebiger W, Scheith-
auer W: Subcutaneous administration of amifostine: A prom-
ising therapeutic option in patients with oxaliplatin-related
peripheral sensitive neuropathy.  Ann Oncol 2001, 12:421-422.
37. Rudolph S, Fahlke J, Fenchel K, Fenchel K, Lippert H, Ridwelski K:
Randomized trial with or without amifostine to reduce neu-
rotoxic side effects under chemotherapy with oxaliplatin (L-
OHP), FA/5-FU.  Proc Am Soc Clin Oncol 2001, 20:302b. abstr 2958
38. Preiss J, Meisel O: Successful auricular neural therapy in oxali-
platin-induced sensory neuropathy.  Proc Am Soc Clin Oncol 2003,
22:362. abstr 1454
39. Afafitei RD, Schneider S, Iqbal S, Yang D, Groshen S, Lenz HJ: Effect
of celecoxib on neurotoxicity in patients with metastatic
colorectal cancer treated with 5-FU/oxaliplatin.  Proc Am Soc
Clin Oncol 2004, 22(14S):270s. abstract 3600
40. De Gramont A, Cervantes G, Andre T, Figer A, Lledo G, Flesch M,
Mineur L, Russ G, Quinaux E, Etienne P-L: OPTIMOX study:
FOLFOX7/LV5FU2 compared to FOLFOX 4 in patients
with advanced colorectal cancer.  Proc Am Soc Clin Oncol 2004,
22(14S):251s. abstr 3525
41. Stein ME, Drumea K, Yarnitsky D, Benny A, Tzuk-Shina T: A rare
event of 5-fluorouracil-associated peripheral neuropathy: a
report of two patients.  Am J Clin Oncol 1998, 21:248-249.
42. Saif MW, Wilson RH, Harold N, Keith B, Dougherty DS, Grem JL:
Peripheral neuropathy associated with weekly oral 5-fluor-
ouracil, leucovorin and eniluracil.  Anti-Cancer Drugs 2001,
12:525-531.
43. Saif MW, Wood TE, McGee PJ, Diasio RB: Peripheral neuropathy
associated with capecitabine.  Anti-Cancer Drugs 2004,
15:767-771.
44. Couch LS, Groteluschen DL, Stewart JA, Mulkerin DL: Capecitab-
ine-related neurotoxicity presenting as trismus.  Clin Colorectal
Cancer 2003, 3:121-123.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/5/116/pre
pub